Barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancer
Provided herein are novel barbituric acid derivatives, their synthesis and use thereof in blocking leukocyte transmigration. The novel barbituric acid derivatives are useful for the treatment of disorders associated with leukocyte transmigration, such as for example inflammatory diseases and disorders, autoimmune diseases and disorders, and cancers.
1. A compound selected from the compounds of Formula 1, Formula 5, Formula 6, Formula 7 and Formula 9:
or
pharmaceutically acceptable salts thereof.
2. A pharmaceutical composition comprising one or more of compounds of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier and/or diluent.
3. A method of inhibiting leukocyte transmigration in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of general Formula (Ib)
wherein
Z is for each phenyl ring independently one or two functional groups; each Z is attached to any available carbon atom of the ring in which it is present; at least one Z is present, and each Z is independently selected from linear alkyl or branched alkyl, wherein each of the linear alkyl or the branched alkyl may be unsubstituted or substituted with one or more of halo, haloalkyl, cyano, nitro, hydroxyl, alkenyl, aryl, alkoxy, aryloxy, aralkoxy, alkylcarbamido, arylcarbamido, amino, alkylamino, arylamino, dialkylamino, diarylamino, arylalkylamino, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, carboxyl, carboxylic ester, alkoxycarbonyl, aryloxycarbonyl, sulfo, alkylsulfonylamido, alkylsulfonyl, arylsulfonyl, alkylsulfinyl, arylsulfinyl;
R 5 is alkyl, selected from linear alkyl or branched alkyl, wherein the alkyl may be unsubstituted or substituted with one, two, or three substituents selected from the group consisting of halo, nitro, cyano and amino; and
stereoisomers, enantiomers, and tautomers thereof, pharmaceutically acceptable salts thereof and mixtures thereof.
4. The method of claim 3 , wherein in the compound of general Formula (Ib) one or two Z are present on one ring and are absent on the other ring.
5. The method of claim 3 , wherein in the compound of general Formula (Ib) one or two Z are present on both rings.
6. The method of claim 3 , wherein in the compound of general Formula (Ib) one or two Z are present on the phenyl ring connected to the barbituric moiety and Z is absent on the other ring.
7. The method of claim 3 , wherein in the compound of general Formula (Ib) two Z are present.
8. The method of claim 3 , wherein in the compound of general Formula (Ib) two Z are present on the same phenyl ring.
9. The method of claim 3 , wherein in the compound of general Formula (Ib) each Z is independently selected from unsubstituted linear alkyl or unsubstituted branched alkyl.
10. The method of claim 9 , wherein in the compound of general Formula (Ib) each Z is independently selected from unsubstituted linear alkyl or unsubstituted branched alkyl, having 1 to 6 carbon atoms (C 1-6 alkyl).
11. The method of claim 10 , wherein in the compound of general Formula (Ib) each Z is independently selected from methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, neo-pentyl, tert-pentyl, n-hexyl, and iso-hexyl, preferably from methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec-butyl, or tert-butyl.
12. The method of claim 3 , wherein in the compound of general Formula (Ib) R 5 is substituted with one, two, or three substituents selected from the group consisting of halo, nitro, cyano and amino.
13. The method of claim 3 , wherein in the compound of general Formula (Ib) R 5 is unsubstituted.
14. The method of claim 3 , wherein in the compound of general Formula (Ib) the carboxylic group —CO(═O)R 5 is present at the para position to the linking group —O—CH 2 —.
15. The method of claim 3 , wherein in the compound of general Formula (Ib) the carboxylic group —CO(═O)R 5 is present at the meta position to the linking group —O—CH 2 —.
16. The method of claim 3 , wherein in the compound of general Formula (Ib) wherein the carboxylic group —CO(═O)R 5 is present at the ortho position to the linking group —O—CH 2 —.
17. The method of claim 3 , wherein in the compound of general Formula (Ib) the bonds to the barbituric acid moiety and to the linking group —O—CH 2 — are located para to each other.
18. The method of claim 3 , wherein in the compound of general Formula (Ib) the bonds to the barbituric acid moiety and to the linking group —O—CH 2 — are located meta to each other.
19. The method of claim 3 , wherein in the compound of general Formula (Ib) the bonds to the barbituric acid moiety and to the linking group —O—CH 2 — are located ortho to each other.
20. The method of claim 3 , wherein the compound of general Formula (Ib) is a compound of Formula 2:
or pharmaceutically acceptable salt thereof.
21. The method of claim 3 , wherein the compound of general Formula (Ib) is a compound of Formula 4:
or pharmaceutically acceptable salt thereof.
22. The method of claim 3 , for treating a disease or condition associated with leukocyte transmigration.
23. The method of claim 22 , wherein the disease or condition is selected from inflammatory diseases and disorders, autoimmune diseases and disorders, and cancers.
24. A method of inhibiting leukocyte transmigration in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound as defined in claim 1 .
25. The method of claim 24 , for treating a disease or condition associated with leukocyte transmigration.
26. The method of claim 25 , wherein the disease or condition is selected from inflammatory diseases and disorders, autoimmune diseases and disorders, and cancers.
27. A method of inhibiting leukocyte transmigration in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula 10:
or pharmaceutically acceptable salt thereof.
28. The method of claim 27 , for treating a disease or condition associated with leukocyte transmigration, wherein the disease or condition is selected from inflammatory diseases and disorders, autoimmune diseases and disorders, and cancers.